News & Publications - Page 2 of 7

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm Reports First Quarter 2020 Financial Results

  • KemPharm to Report First Quarter 2020 Financial Results

  • NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital

  • KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD

  • KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results

  • Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement

  • KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital

  • KemPharm Reports Third Quarter 2019 Results

  • KemPharm to Report Third Quarter 2019 Results

  • KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019

  • KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting

  • KemPharm Provides Updates Regarding its Board of Directors